Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e90-

  Fenard, David ^a,b   Ingrao, Dina ^a,b   Seye, Ababacar ^a,b   Buisset, Julien ^a,b   Genries, Sandrine ^a,b   Martin, Samia ^a   Kichler, Antoine ^a,c,d,e   Galy, Anne ^a,b  

^a GÉNÉTHON   (France)

^b UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^c CNRS   (France)

^d Centre National de la Recherche Scientifique   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cationic peptide; Gene therapy; Hematopoietic stem cell; Lentiviral vector

Indexed keywords

ENHANCEOSOME; FIBRONECTIN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VECTOFUSIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD34 SELECTION; CELL ADHESION; CONTROLLED STUDY; COPY NUMBER VARIATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE FUSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENTRY;

EID: 84878870410     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.17     Document Type: Article

References (50)

1. D'Costa, J, Mansfield, SG and Humeau, LM (2009). Lentiviral vectors in clinical trials: Current status. Curr Opin Mol Ther 11: 554-564.
2. Naldini, L (2011). Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12: 301-315.
3. Cronin, J, Zhang, XY and Reiser, J (2005). Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5: 387-398. (Pubitemid 41052430)
4. Merten, OW, Charrier, S, Laroudie, N, Fauchille, S, Dugué, C, Jenny, C et al. (2011). Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22: 343-356.
5. Sandrin, V, Boson, B, Salmon, P, Gay, W, Nègre, D, Le Grand, R et al. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100: 823-832. (Pubitemid 34832607)
6. Cornetta, K and Anderson, WF (1989). Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. J Virol Methods 23: 187-194. (Pubitemid 19069996)
7. Toyoshima, K and Vogt, PK (1969). Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology 38: 414-426.
8. Vogt, PK (1967). DEAE-dextran: enhancement of cellular transformation induced by avian sarcoma viruses. Virology 33: 175-177.
9. Innes, CL, Smith, PB, Langenbach, R, Tindall, KR and Boone, LR (1990). Cationic liposomes (Lipofectin) mediate retroviral infection in the absence of specific receptors. J Virol 64: 957-961. (Pubitemid 20032720)
10. Hodgson, CP and Solaiman, F (1996). Virosomes: cationic liposomes enhance retroviral transduction. Nat Biotechnol 14: 339-342. (Pubitemid 26149077)
11. Wurm, M, Schambach, A, Lindemann, D, Hanenberg, H, Ständker, L, Forssmann, WG et al. (2010). The influence of semen-derived enhancer of virus infection on the efficiency of retroviral gene transfer. J Gene Med 12: 137-146.
12. Davis, HE, Rosinski, M, Morgan, JR and Yarmush, ML (2004). Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 86: 1234-1242. (Pubitemid 38209565)
13. Roan, NR, Münch, J, Arhel, N, Mothes, W, Neidleman, J, Kobayashi, A et al. (2009). The cationic properties of SEVI underlie its ability to enhance huma n immunodeficiency virus infection. J Virol 83: 73-80.
14. Moritz, T, Patel, VP and Williams, DA (1994). Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J Clin Invest 93: 1451-1457.
15. Moritz, T, Dutt, P, Xiao, X, Carstanjen, D, Vik, T, Hanenberg, H et al. (1996). Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88: 855-862. (Pubitemid 26333306)
16. Hanenberg, H, Xiao, XL, Dilloo, D, Hashino, K, Kato, I and Williams, DA (1996). Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 2: 876-882. (Pubitemid 26296757)
17. Haas, DL, Case, SS, Crooks, GM and Kohn, DB (2000). Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol Ther 2: 71-80.
18. Kichler, A, Leborgne, C, März, J, Danos, O and Bechinger, B (2003). Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells. Proc Natl Acad Sci USA 100: 1564-1568. (Pubitemid 36254487)
19. Bechinger, B, Vidovic, V, Bertani, P and Kichler, A (2011). A new family of peptide-nucleic acid nanostructures with potent transfection activities. J Pept Sci 17: 88-93.
20. Mason, AJ, Gasnier, C, Kichler, A, Prévost, G, Aunis, D, Metz-Boutigue, MH et al. (2006). Enhanced membrane disruption and antibiotic action against pathogenic bacteria by designed histidine-rich peptides at acidic pH. Antimicrob Agents Chemother 50: 3305-3311. (Pubitemid 44527502)
21. Mason, AJ, Martinez, A, Glaubitz, C, Danos, O, Kichler, A and Bechinger, B (2006). The antibiotic and DNA-transfecting peptide LAH4 selectively associates with, and disorders, anionic lipids in mixed membranes. FASEB J 20: 320-322. (Pubitemid 46671157)
22. Marquette, A, Mason, AJ and Bechinger, B (2008). Aggregation and membrane permeabilizing properties of designed histidine-containing cationic linear peptide antibiotics. J Pept Sci 14: 488-495. (Pubitemid 351540911)
23. Mason, AJ, Moussaoui, W, Abdelrahman, T, Boukhari, A, Bertani, P, Marquette, A et al. (2009). Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides. J Biol Chem 284: 119-133.
24. Langlet-Bertin, B, Leborgne, C, Scherman, D, Bechinger, B, Mason, AJ and Kichler, A (2010). Design and evaluation of histidine-rich amphipathic peptides for siRNA delivery. Pharm Res 27: 1426-1436.
25. Ferrer-Miralles, N, Vázquez, E and Villaverde, A (2008). Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol 26: 267-275.
26. Cavrois, M, De Noronha, C and Greene, WC (2002). A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20: 1151-1154. (Pubitemid 35285446)
27. Cavrois, M, Neidleman, J, Bigos, M and Greene, WC (2004). Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol 263: 333-344.
28. Jacome, A, Navarro, S, Río, P, Yañez, RM, González-Murillo, A, Lozano, ML et al. (2009). Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther 17: 1083-1092.
29. Relander, T, Johansson, M, Olsson, K, Ikeda, Y, Takeuchi, Y, Collins, M et al. (2005). Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther 11: 452-459. (Pubitemid 40277322)
30. Münch, J, Rücker, E, Ständker, L, Adermann, K, Goffinet, C, Schindler, M et al. (2007). Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131: 1059-1071. (Pubitemid 350235017)
31. Pollok, KE, van Der Loo, JC, Cooper, RJ, Hartwell, JR, Miles, KR, Breese, R et al. (2001). Differential transduction efficiency of SCID-repopulating cells derived from umbilical cord blood and granulocyte colony-stimulating factor-mobilized peripheral blood. Hum Gene Ther 12: 2095-2108. (Pubitemid 34053493)
32. Charrier, S, Ferrand, M, Zerbato, M, Précigout, G, Viornery, A, Bucher-Laurent, S et al. (2011). Quantification of lentiviral vector copy numbers in individual hematopoietic colonyforming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene Ther 18: 479-487.
33. Legrand, N, Weijer, K and Spits, H (2008). Experimental model for the study of the human immune system: production and monitoring of "human immune system" Rag2-/-gamma c-/- mice. Methods Mol Biol 415: 65-82.
34. Georgescu, J, Munhoz, VH and Bechinger, B (2010). NMR structures of the histidine-rich peptide LAH4 in micellar environments: membrane insertion, pH-dependent mode of antimicrobial action, and DNA transfection. Biophys J 99: 2507-2515.
35. Bonini, C, Grez, M, Traversari, C, Ciceri, F, Marktel, S, Ferrari, G et al. (2003). Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9: 367-369. (Pubitemid 36460048)
36. de la Vega, M, Marin, M, Kondo, N, Miyauchi, K, Kim, Y, Epand, RF et al. (2011). Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology 8: 99.
37. Jha, NK, Latinovic, O, Martin, E, Novitskiy, G, Marin, M, Miyauchi, K et al. (2011). Imaging single retrovirus entry through alternative receptor isoforms and intermediates of virusendosome fusion. PLoS Pathog 7: e1001260.
38. Miyauchi, K, Kim, Y, Latinovic, O, Morozov, V and Melikyan, GB (2009). HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137: 433-444.
39. Chien, MP, Lin, CH and Chang, DK (2009). Recruitment of HIV-1 envelope occurs subsequent to lipid mixing: a fluorescence microscopic evidence. Retrovirology 6: 20.
40. Frecha, C, Costa, C, Nègre, D, Gauthier, E, Russell, SJ, Cosset, FL et al. (2008). Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112: 4843-4852.
41. Funke, S, Schneider, IC, Glaser, S, Mühlebach, MD, Moritz, T, Cattaneo, R et al. (2009). Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther 16: 700-705.
42. Enkirch, T, Kneissl, S, Hoyler, B, Ungerechts, G, Stremmel, W, Buchholz, CJ et al. (2013). Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins. Gene Ther 20: 16-23.
43. Funke, S, Maisner, A, Mühlebach, MD, Koehl, U, Grez, M, Cattaneo, R et al. (2008). Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427-1436.
44. Anliker, B, Abel, T, Kneissl, S, Hlavaty, J, Caputi, A, Brynza, J et al. (2010). Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7: 929-935.
45. Münch, RC, Mühlebach, MD, Schaser, T, Kneissl, S, Jost, C, Plückthun, A et al. (2011). DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 19: 686-693.
46. Lamers, CH, van Elzakker, P, van Steenbergen, SC, Sleijfer, S, Debets, R and Gratama, JW (2008). Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield. Cytotherapy 10: 406-416. (Pubitemid 351983164)
47. Guilak, F, Cohen, DM, Estes, BT, Gimble, JM, Liedtke, W and Chen, CS (2009). Control of stem cell fate by physical interactions with the extracellular matrix. Cell Stem Cell 5: 17-26.
48. Galy, A and Thrasher, AJ (2011). Gene therapy for the Wiskott-Aldrich syndrome. Curr Opin Allergy Clin Immunol 11: 545-550.
49. Kutner, RH, Zhang, XY and Reiser, J (2009). Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4: 495-505.
50. Merten, OW (2004). State-of-the-art of the production of retroviral vectors. J Gene Med 6 (suppl. 1): S105-S124.